Moe Alsumidaie’s Post

View profile for Moe Alsumidaie, graphic

Clinical Trial Industry Expert

A recent study published in BMC Veterinary Research highlights the efficacy of OKV-119, a novel miniature drug implant, in reducing weight in obese cats. This implant, utilizing Vivani Medical’s NanoPortal technology, delivers exenatide for long-term weight management. Exenatide aids in regulating blood sugar levels and facilitating weight loss. The study demonstrated that cats implanted with OKV-119 experienced a significant reduction in weight compared to controls. The sustained release of exenatide over 84 days effectively curbed appetite and boosted energy expenditure, addressing feline obesity, a prevalent health issue affecting up to 40% of domestic cats. OKV-119's development is a promising advancement in combating feline obesity. Its convenient administration and prolonged effectivity present a groundbreaking solution to enhance feline health and combat associated conditions like diabetes, heart disease, and joint pain. Future research aims to extend the implant's duration to six months, further improving its practicality in long-term feline obesity treatment. Read more about this innovative solution in veterinary care: https://lnkd.in/dWfmBrch Adam Mendelsohn Linda Adreveno

ViVani Medical Unveils Groundbreaking Weight Loss Solution for Pets with OKV-119: A Life-Changing Innovation

ViVani Medical Unveils Groundbreaking Weight Loss Solution for Pets with OKV-119: A Life-Changing Innovation

https://www.clinicaltrialvanguard.com

To view or add a comment, sign in

Explore topics